[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SEED Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100608130",false,"NCT07197554","A Phase 1\u002F1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.\n* Has a metastatic or locally advanced and unresectable solid tumor.\n* Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.\n* Has an ECOG performance status ≤ 2 at screening.\n* Has adequate organ function as defined in the protocol.\n\nExclusion Criteria:\n\n* Has received prior radiotherapy within 2 weeks of treatment.\n* Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable\n* Has received treatment with any local or systemic anticancer therapy or investigational anticancer agent within 14 days or 5 half-lives, whichever is shorter.\n* Had major surgery within 28 days before study therapy administration\n* Has toxicities from previous anticancer therapies that have not resolved to baseline levels, with the exception of alopecia and peripheral neuropathy.\n* Has previously received a RBM39 inhibitor\u002Fdegrader.","ALL","16 Years",{"count":17,"type":18},171,"ESTIMATED","INTERVENTIONAL",[21],"PHASE1","A Phase 1\u002F1B Study of ST-01156 in Patients with Advanced Solid Malignancies",[24,25,26,27],"Advanced Solid Tumors","Ewing Sarcoma","Hepatocellular Carcinoma (HCC)","Biliary Tract Cancer (BTC)",[29,30,31,32,33,34,35,36,37,38,39],"cancer","solid tumors","RBM39","RBM39 degrader","metastatic solid malignancies","Ewing sarcoma","Hepatocellular carcinoma","HCC","Biliary tract carcinoma","endometrial carcinoma","Adolescents","RECRUITING","2026-05-30",{"date":43,"type":44},"2026-06-02","ACTUAL",{"date":46,"type":44},"2025-12-01",{"date":48,"type":18},"2029-12-31",{"name":50,"class":51},"SEED Therapeutics, Inc.","INDUSTRY",6,""]